Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study
Background: We aimed to evaluate the factors associated with a virological response in a cohort of Hepatitis C virus (HCV)-infected people who inject drugs (PWID) treated with direct acting antivirals (DAAs). Methods: We conducted a multicenter retrospective cohort study enrolling HCV-infected PWID...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/11/1/17 |
| _version_ | 1827698999728013312 |
|---|---|
| author | Vincenzo Messina Lorenzo Onorato Giovanni Di Caprio Ernesto Claar Vincenzo Iovinella Antonio Russo Valerio Rosato Angela Salzillo Riccardo Nevola Filomena Simeone Fabio Curcio Mariantonietta Pisaturo Nicola Coppola |
| author_facet | Vincenzo Messina Lorenzo Onorato Giovanni Di Caprio Ernesto Claar Vincenzo Iovinella Antonio Russo Valerio Rosato Angela Salzillo Riccardo Nevola Filomena Simeone Fabio Curcio Mariantonietta Pisaturo Nicola Coppola |
| author_sort | Vincenzo Messina |
| collection | DOAJ |
| description | Background: We aimed to evaluate the factors associated with a virological response in a cohort of Hepatitis C virus (HCV)-infected people who inject drugs (PWID) treated with direct acting antivirals (DAAs). Methods: We conducted a multicenter retrospective cohort study enrolling HCV-infected PWID treated with DAAs. The primary outcome evaluated was the sustained virological response (SVR12) rate. Results: Five hundred and twenty HCV-infected PWID treated with all-oral DAA-based regimens were enrolled; a total of 168 (32.3%) patients presented genotype 1a, 109 (21.0%) genotype 1b, and 174 (33.5%) genotype 3; a total 152 of the 520 subjects (29.2%) were cirrhotics; a total 118 (22.7%) and 373 (71.7%) were treated with DAA regimens of second and third generation, respectively; a total 169 (33.6%) patients were receiving an opioid agonist at the start of antiviral therapy. Only 11 subjects (2.1%) did not show an SVR12. A significant correlation was found between treatment with opioid substitution therapy (<i>p</i> < 0.001), Human Immunodeficiency Virus (HIV) coinfection (<i>p</i> = 0.002), and treatment with first- or second-generation regimens (<i>p</i> = 0.0015) and HCV failure. Upon multivariate analysis, treatment with a first- or second-generation DAA was the only factor independently associated with failure (OR 10.4, 95% CI: 1.43 to 76.1, <i>p</i> = 0.02). Conclusions: Treatment with DAAs led to a high SVR12 rate (97.9%) in a large cohort of HCV-infected PWID. The only predictor of viral failure found in our analysis was treatment with first- and second-generation DAA. |
| first_indexed | 2024-03-10T13:39:55Z |
| format | Article |
| id | doaj.art-a2a0f59353da4496b331240e8e0f490f |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T13:39:55Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-a2a0f59353da4496b331240e8e0f490f2023-11-21T03:08:52ZengMDPI AGLife2075-17292020-12-011111710.3390/life11010017Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life StudyVincenzo Messina0Lorenzo Onorato1Giovanni Di Caprio2Ernesto Claar3Vincenzo Iovinella4Antonio Russo5Valerio Rosato6Angela Salzillo7Riccardo Nevola8Filomena Simeone9Fabio Curcio10Mariantonietta Pisaturo11Nicola Coppola12Infectious Diseases Unit, AORN Sant’Anna e San Sebastiano, 81100 Caserta, ItalyInfectious Diseases Unit, AORN Sant’Anna e San Sebastiano, 81100 Caserta, ItalyInfectious Diseases Unit, AORN Sant’Anna e San Sebastiano, 81100 Caserta, ItalyHepatology Unit, Evangelical Hospital Betania, 80147 Naples, ItalyDepartment of Internal Medicine, San Paolo Hospital, ASL Napoli 1 Centro, 80145 Naples, ItalyInfectious Diseases Unit, AORN Sant’Anna e San Sebastiano, 81100 Caserta, ItalyHepatology Unit, Evangelical Hospital Betania, 80147 Naples, ItalyInfectious Diseases Unit, AORN Sant’Anna e San Sebastiano, 81100 Caserta, ItalyHepatology Unit, Evangelical Hospital Betania, 80147 Naples, ItalyInfectious Diseases Unit, AORN Sant’Anna e San Sebastiano, 81100 Caserta, ItalyUOC Dipendenze Ovest, ASL Napoli 1 Centro, 80145 Naples, ItalyInfectious Diseases Unit, AORN Sant’Anna e San Sebastiano, 81100 Caserta, ItalyInfectious Diseases Unit, AORN Sant’Anna e San Sebastiano, 81100 Caserta, ItalyBackground: We aimed to evaluate the factors associated with a virological response in a cohort of Hepatitis C virus (HCV)-infected people who inject drugs (PWID) treated with direct acting antivirals (DAAs). Methods: We conducted a multicenter retrospective cohort study enrolling HCV-infected PWID treated with DAAs. The primary outcome evaluated was the sustained virological response (SVR12) rate. Results: Five hundred and twenty HCV-infected PWID treated with all-oral DAA-based regimens were enrolled; a total of 168 (32.3%) patients presented genotype 1a, 109 (21.0%) genotype 1b, and 174 (33.5%) genotype 3; a total 152 of the 520 subjects (29.2%) were cirrhotics; a total 118 (22.7%) and 373 (71.7%) were treated with DAA regimens of second and third generation, respectively; a total 169 (33.6%) patients were receiving an opioid agonist at the start of antiviral therapy. Only 11 subjects (2.1%) did not show an SVR12. A significant correlation was found between treatment with opioid substitution therapy (<i>p</i> < 0.001), Human Immunodeficiency Virus (HIV) coinfection (<i>p</i> = 0.002), and treatment with first- or second-generation regimens (<i>p</i> = 0.0015) and HCV failure. Upon multivariate analysis, treatment with a first- or second-generation DAA was the only factor independently associated with failure (OR 10.4, 95% CI: 1.43 to 76.1, <i>p</i> = 0.02). Conclusions: Treatment with DAAs led to a high SVR12 rate (97.9%) in a large cohort of HCV-infected PWID. The only predictor of viral failure found in our analysis was treatment with first- and second-generation DAA.https://www.mdpi.com/2075-1729/11/1/17PWIDDAAHCV infectionHCV chronic hepatitisHCV treatmentInterferon-free |
| spellingShingle | Vincenzo Messina Lorenzo Onorato Giovanni Di Caprio Ernesto Claar Vincenzo Iovinella Antonio Russo Valerio Rosato Angela Salzillo Riccardo Nevola Filomena Simeone Fabio Curcio Mariantonietta Pisaturo Nicola Coppola Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study Life PWID DAA HCV infection HCV chronic hepatitis HCV treatment Interferon-free |
| title | Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study |
| title_full | Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study |
| title_fullStr | Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study |
| title_full_unstemmed | Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study |
| title_short | Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study |
| title_sort | directly acting antiviral based treatment for hcv infected persons who inject drugs a multicenter real life study |
| topic | PWID DAA HCV infection HCV chronic hepatitis HCV treatment Interferon-free |
| url | https://www.mdpi.com/2075-1729/11/1/17 |
| work_keys_str_mv | AT vincenzomessina directlyactingantiviralbasedtreatmentforhcvinfectedpersonswhoinjectdrugsamulticenterreallifestudy AT lorenzoonorato directlyactingantiviralbasedtreatmentforhcvinfectedpersonswhoinjectdrugsamulticenterreallifestudy AT giovannidicaprio directlyactingantiviralbasedtreatmentforhcvinfectedpersonswhoinjectdrugsamulticenterreallifestudy AT ernestoclaar directlyactingantiviralbasedtreatmentforhcvinfectedpersonswhoinjectdrugsamulticenterreallifestudy AT vincenzoiovinella directlyactingantiviralbasedtreatmentforhcvinfectedpersonswhoinjectdrugsamulticenterreallifestudy AT antoniorusso directlyactingantiviralbasedtreatmentforhcvinfectedpersonswhoinjectdrugsamulticenterreallifestudy AT valeriorosato directlyactingantiviralbasedtreatmentforhcvinfectedpersonswhoinjectdrugsamulticenterreallifestudy AT angelasalzillo directlyactingantiviralbasedtreatmentforhcvinfectedpersonswhoinjectdrugsamulticenterreallifestudy AT riccardonevola directlyactingantiviralbasedtreatmentforhcvinfectedpersonswhoinjectdrugsamulticenterreallifestudy AT filomenasimeone directlyactingantiviralbasedtreatmentforhcvinfectedpersonswhoinjectdrugsamulticenterreallifestudy AT fabiocurcio directlyactingantiviralbasedtreatmentforhcvinfectedpersonswhoinjectdrugsamulticenterreallifestudy AT mariantoniettapisaturo directlyactingantiviralbasedtreatmentforhcvinfectedpersonswhoinjectdrugsamulticenterreallifestudy AT nicolacoppola directlyactingantiviralbasedtreatmentforhcvinfectedpersonswhoinjectdrugsamulticenterreallifestudy |